CRMD vs UNH

CorMedix Inc. exhibits significantly de-risked commercialization with exceptional Q1 2026 results, reporting $127.4 million in revenue and $38.6 million in net income, handily beating revenue estimates. The company substantially raised its FY2026 guidance to $325M-$345M revenue and $115M-$135M adjusted EBITDA, demonstrating strong market adoption of DefenCath and effective integration of the Melin...

UnitedHealth Group (UNH) remains a robust, high-quality mega-cap in the mature and highly regulated healthcare sector. Q1 2026 adjusted EPS of $7.23, a recent dividend increase to $2.32, and some analyst upgrades (e.g., Truist to $440, Goldman Sachs Conviction Buy) reflect solid operational performance and financial strength. However, these are characteristics of a stable compounder, not a company...